A Study to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic Dermatitis

NCT04162769 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

140

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis

Interventions

DRUG: Etrasimod 1 mg
DRUG: Etrasimod 2 mg
DRUG: Etrasimod matching placebo

Sponsor

Arena Pharmaceuticals